Trillium Therapeutics Stock
Your prediction
Trillium Therapeutics Stock
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Trillium Therapeutics stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Trillium Therapeutics in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
B****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Trillium Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Trillium Therapeutics | - | - | - | - | - | - | - |
| Resverlogix Corp | 2.310% | -2.985% | 12.069% | 116.667% | 140.741% | -43.966% | -88.393% |
| Enwave Corporation | -3.510% | 8.571% | 1.786% | 88.430% | 65.217% | -26.452% | -70.157% |
| Aurinia Pharmaceuticals Inc. | -0.340% | -4.180% | 6.092% | 61.566% | 53.538% | 202.743% | 7.452% |
Comments
News
Tvardi Posts Q2 Net Income Turnaround
Tvardi Therapeutics (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on developing new therapies for serious diseases, released its second quarter fiscal 2025 results on August 14
